STAT July 5, 2024
Lynn Brielmaier

One night in November 2018, I fell while crossing a street in Subic Bay, a U.S. naval logistics station in The Philippines. My face whacked the asphalt. Lying in the path of oncoming traffic, I couldn’t move a muscle. After 45 seconds of terror, I was able to stand up and haul myself to the other side.

Six months later, after dealing with symptoms like my left leg buckling unexpectedly and being extra tired hauling my tools around on the job, a doctor told me I had amyotrophic lateral sclerosis — a 100% fatal disease. “What’s going to happen?” I asked. “You’re going to be paralyzed,” he said.

At the time I was a 59-year-old father and husband. My work...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
Pharma Pulse 10/3/24: Data Collection Complexities, 8 Things You May Not Know About Breast Cancer & more
New Techniques Make RNA Accessible to Study Variants of Uncertain Significance
Comprehensive strategies for prescription drug cost management
Gilead strikes deal to expand HIV drug access in 120 countries

Share This Article